Secrecy Outage on Transmit Antenna Selection/Maximal Ratio Combining in MIMO Cognitive Radio Networks

This paper investigates the secrecy outage performance of transmit antenna selection (TAS)/maximal ratio combining (MRC) in multiple input multiple output (MIMO) cognitive radio networks (CRNs) over Rayleigh fading channels. In the considered system, a secondary user (SU-TX) equipped with NA (NA 1) antennas uses TAS to transmit confidential messages to another secondary user (SU-RX), which is equipped with NB (NB 1) antennas and adopts MRC scheme to process multiple received signals. Meanwhile, an eavesdropper equipped with NE (NE 1) antennas also adopts MRC scheme to overhear the transmitted information between SU-TX and SU-RX. SU-TX adopts the underlay strategy to guarantee the quality of service of the primary user without spectrum sensing. In this paper, we derive the exact and asymptotic closed-form expressions for the secrecy outage probability. Simulations are conducted to validate the accuracy of the analysis.ARC Discovery Projects Grant DP150103905

Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.

BACKGROUND Histone acetylation/deacetylase process is one of the most studied epigenetic modifications. Histone deacetylase inhibitors (HDACis) have shown clinical benefits in haematological malignancies but failed in solid tumours due to the lack of biomarker-driven stratification. METHODS We perform integrative pharmaco-transcriptomic analysis by correlating drug response profiles of five pan-HDACis with transcriptomes of solid cancer cell lines (n=659) to systematically identify generalizable gene signatures associated with HDACis sensitivity and resistance. The established signatures are then applied to identify cancer subtypes that are potentially sensitive or resistant to HDACis, and drugs that enhance the efficacy of HDACis. Finally, the reproductivity of the established HDACis signatures is evaluated by multiple independent drug response datasets and experimental assays. FINDINGS We successfully delineate generalizable gene signatures predicting sensitivity (containing 46 genes) and resistance (containing 53 genes) to all five HDACis, with their reproductivity confirmed by multiple external sources and independent internal assays. Using the gene signatures, we identify low-grade glioma harbouring isocitrate dehydrogenase 1/2 (IDH1/2) mutation and non-YAP1-driven subsets of small-cell lung cancer (SCLC) that particularly benefit from HDACis monotherapy. Further, based on the resistance gene signature, we identify clinically-approved Dasatinib as a synthetic lethal drug with HDACi, synergizing in inducing apoptosis and reactive oxygen species on a panel of SCLC. Finally, Dasatinib significantly enhances the therapeutic efficacy of Vorinostat in SCLC xenografts. INTERPRETATION Our work establishes robust gene signatures predicting HDACis sensitivity/resistance in solid cancer and uncovers combined Dasatinib/HDACi as a synthetic lethal combination therapy for SCLC

Performance of first insert coil with REBCO CICC sub-size cable exceeding 6 kA at 21 T magnetic field

The Institute of Plasma Physics at the Chinese Academy of Sciences is developing the REBCO cable in conduit conductor (CICC) technology for applications in next-generation nuclear fusion devices. The aim is to develop a CICC comprised of six REBCO sub-cables to satisfy the requirements of operation with a current of around 40 kA and a peak field of up to 20 T. To qualify the performance of the sub-size REBCO cable to be used in the CICC, two 25-turn insert solenoids have been designed, manufactured and tested at a current exceeding 6 kA subjected in a background field supplied by a water-cooled resistive magnet. The insert solenoid, wound from a 11.5 m long REBCO CORC$^{®}$ cable, was designed to investigate its current carrying capacity under high field and electromagnetic (EM) load at 4.2 K. Tests were performed under a background magnetic field up to 18.5 T, resulting in a peak magnetic field on the innermost layer turns of around 21.1 T at an operating current of 6.3 kA. The effects of operation with cyclic EM loads were tested by repeated current ramps to around 95% of the critical current. Moreover, the V–I characteristics were measured at 77 K and the self-field, to check the effects from warm-up and cool-down (WUCD) cycles between room temperature and 77 K with liquid nitrogen. The results show no obvious degradation after dozens of high-current test cycles in background fields ranging from 10 T to 18.5 T. The insert solenoid demonstrates the stable operation of the REBCO sub-size cable for CICC with EM loads of about 90 kN m$^{−1}$ and WUCD cycles between room temperature and 77 K. These promising results indicate the potential of this technology for further applicationsin particular, for full-size CICC for high-performance fusion magnets

p53/p21 Pathway Involved in Mediating Cellular Senescence of Bone Marrow-Derived Mesenchymal Stem Cells from Systemic Lupus Erythematosus Patients

Our and other groups have found that bone marrow-derived mesenchymal stem cells (BM-MSCs) from systemic lupus erythematosus (SLE) patients exhibited senescent behavior and are involved in the pathogenesis of SLE. Numerous studies have shown that activation of the p53/p21 pathway inhibits the proliferation of BM-MSCs. The aim of this study was to determine whether p53/p21 pathway is involved in regulating the aging of BM-MSCs from SLE patients and the underlying mechanisms. We further confirmed that BM-MSCs from SLE patients showed characteristics of senescence. The expressions of p53 and p21 were significantly increased, whereas levels of Cyclin E, cyclin-dependent kinase-2, and phosphorylation of retinoblastoma protein were decreased in the BM-MSCs from SLE patients and knockdown of p21 expression reversed the senescent features of BM-MSCs from SLE patients. Our results demonstrated that p53/p21 pathway played an important role in the senescence process of BM-MSCs from SLE